Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Other Working Capital Changes for 8 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 410.23% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at $17.9 million (up 2610.27% YoY), while the FY2025 annual figure was $20.8 million, up 6806.13% from the prior year.
• Other Working Capital Changes improved to -$2.2 million in Q1 2026 per KYMR's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $14.2 million in Q4 2023 and bottomed at -$5.2 million in Q3 2023.
• Historically, Other Working Capital Changes has averaged $1.2 million across 5 years, with a median of $480000.0 in 2022.
• On a YoY basis, Other Working Capital Changes climbed as much as 3914.04% in 2025 and fell as far as 1350.0% in 2025.
• Kymera Therapeutics' Other Working Capital Changes stood at $24.4 million in 2022, then tumbled by 97.91% to $511000.0 in 2023, then slumped by 138.75% to -$198000.0 in 2024, then sank by 1350.0% to -$2.9 million in 2025, then increased by 25.01% to -$2.2 million in 2026.
• Business Quant data shows KYMR's Other Working Capital Changes at -$2.2 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.8 million in Q3 2025.